Mink Therapeutics (INKT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 May, 2026Executive summary
Annual meeting scheduled for June 17, 2026, to be held virtually, with voting available online, by phone, mail, or during the meeting.
Stockholders as of April 23, 2026, are eligible to vote on director elections and auditor ratification.
Proxy materials are distributed via internet access, with options for printed copies and electronic delivery to reduce environmental impact.
A one-for-ten reverse stock split was effected on January 28, 2025.
Voting matters and shareholder proposals
Election of three Class II directors (Garo Armen, Barbara Ryan, John Holcomb) for three-year terms expiring at the 2029 annual meeting.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Board recommends voting FOR all nominees and auditor ratification.
Shareholders may submit proposals for the 2027 annual meeting by December 30, 2026, following specific procedures.
Board of directors and corporate governance
Board consists of seven members divided into three classes, with annual elections for one class.
Majority of directors are independent; annual self-evaluations and performance assessments are conducted.
Three standing committees: Audit and Finance, Compensation, and Corporate Governance and Nominating; an Affiliate Transactions Committee addresses conflicts with Agenus.
Code of Ethics and Securities Trading Policy updated in 2023; independent directors meet in executive session.
Latest events from Mink Therapeutics
- Phase II trial for agenT-797 advanced, early benefit seen; cash $8.8M, funding uncertainty persists.INKT
Q2 2026 - Directors and auditor elected, immune restoration strategy advanced, and global trials expanded.INKT
AGM 2026 - Advanced iNKT cell therapy into Phase II trials, expanded platform, and maintained $9.5M cash.INKT
Q1 2026 - Durable clinical results, strong cash position, and major trial milestones expected in 2026.INKT
Q4 2025 - Net loss narrowed, cash burn fell, and clinical progress continues amid funding risks.INKT
Q3 2024 - iNKT cell therapies show promise in hard-to-treat cancers and ARDS, with pivotal trials underway.INKT
H.C. Wainwright 26th Annual Global Investment Conference 2024 - Net loss narrowed, cash increased, and iNKT pipeline advanced, but funding risks remain.INKT
Q2 2024 - Clinical advances, reduced cash burn, and NIAID funding support growth amid liquidity risks.INKT
Q1 2025 - Net loss narrowed, cash burn fell, and clinical pipeline advanced toward 2025 milestones.INKT
Q4 2024